Trillium Asset Management LLC Sells 1,855 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Trillium Asset Management LLC lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 64,265 shares of the medical research company’s stock after selling 1,855 shares during the quarter. Trillium Asset Management LLC’s holdings in IQVIA were worth $12,629,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Smith Group Asset Management LLC acquired a new position in shares of IQVIA during the fourth quarter worth $1,616,000. Nordea Investment Management AB lifted its holdings in shares of IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares during the period. Hickory Asset Management Inc. acquired a new position in shares of IQVIA during the fourth quarter worth $941,000. Fifth Third Bancorp lifted its holdings in shares of IQVIA by 13.0% during the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after purchasing an additional 1,521 shares during the period. Finally, Graphene Investments SAS lifted its holdings in shares of IQVIA by 22.0% during the fourth quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock worth $2,948,000 after purchasing an additional 2,700 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of NYSE:IQV opened at $188.45 on Wednesday. The company’s fifty day moving average price is $196.06 and its 200-day moving average price is $209.52. The firm has a market capitalization of $33.23 billion, a price-to-earnings ratio of 25.13, a PEG ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a one year low of $179.28 and a one year high of $256.34. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on IQV shares. JPMorgan Chase & Co. cut their price target on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. Stifel Nicolaus dropped their target price on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Leerink Partners restated an “outperform” rating and issued a $248.00 target price (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Finally, Stephens started coverage on shares of IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 target price on the stock. Five research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.